Prevalence of IgG and Neutralizing Antibodies against Staphylococcus aureus Alpha-Toxin in Healthy Human Subjects and Diverse Patient Populations
Staphylococcus aureus causes an array of serious infections resulting in high morbidity and mortality worldwide. This study evaluated naturally occurring serum anti-alpha-toxin (anti-AT) antibody levels in human subjects from various age groups, individuals with S. aureus dialysis and surgical-site...
Saved in:
Published in | Infection and immunity Vol. 86; no. 3 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Society for Microbiology
01.03.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Staphylococcus aureus
causes an array of serious infections resulting in high morbidity and mortality worldwide. This study evaluated naturally occurring serum anti-alpha-toxin (anti-AT) antibody levels in human subjects from various age groups, individuals with
S. aureus
dialysis and surgical-site infections, and
S. aureus
-colonized versus noncolonized subjects. Anti-AT immunoglobulin G (IgG) and neutralizing antibody (NAb) levels in infants (aged ≤1 year) were significantly lower than those in other populations. In comparison to adolescent, adult, and elderly populations, young children (aged 2 to 10 years) had equivalent anti-AT IgG levels but significantly lower anti-AT NAb levels. Therefore, the development of anti-AT NAbs appears to occur later than that of AT-specific IgG, suggesting a maturation of the immune response to AT. Anti-AT IgG levels were slightly higher in
S. aureus
-colonized subjects than in noncolonized subjects. The methicillin susceptibility status of colonizing isolates had no effect on anti-AT antibody levels in
S. aureus
-colonized subjects. The highest anti-AT IgG and NAb levels were observed in dialysis patients with acute
S. aureus
infection. Anti-AT IgG and NAb levels were well correlated in subjects aged >10 years, regardless of colonization or infection status. These data demonstrate that AT elicits a robust IgG humoral response in infants and young children that becomes stable prior to adolescence, matures into higher levels of NAbs in healthy adolescents, and becomes elevated during
S. aureus
infection. These findings may assist in identifying subjects and patient populations that could benefit from vaccination or immunoprophylaxis with anti-AT monoclonal antibodies. |
---|---|
AbstractList | Staphylococcus aureus
causes an array of serious infections resulting in high morbidity and mortality worldwide. This study evaluated naturally occurring serum anti-alpha-toxin (anti-AT) antibody levels in human subjects from various age groups, individuals with
S. aureus
dialysis and surgical-site infections, and
S. aureus
-colonized versus noncolonized subjects. Anti-AT immunoglobulin G (IgG) and neutralizing antibody (NAb) levels in infants (aged ≤1 year) were significantly lower than those in other populations. In comparison to adolescent, adult, and elderly populations, young children (aged 2 to 10 years) had equivalent anti-AT IgG levels but significantly lower anti-AT NAb levels. Therefore, the development of anti-AT NAbs appears to occur later than that of AT-specific IgG, suggesting a maturation of the immune response to AT. Anti-AT IgG levels were slightly higher in
S. aureus
-colonized subjects than in noncolonized subjects. The methicillin susceptibility status of colonizing isolates had no effect on anti-AT antibody levels in
S. aureus
-colonized subjects. The highest anti-AT IgG and NAb levels were observed in dialysis patients with acute
S. aureus
infection. Anti-AT IgG and NAb levels were well correlated in subjects aged >10 years, regardless of colonization or infection status. These data demonstrate that AT elicits a robust IgG humoral response in infants and young children that becomes stable prior to adolescence, matures into higher levels of NAbs in healthy adolescents, and becomes elevated during
S. aureus
infection. These findings may assist in identifying subjects and patient populations that could benefit from vaccination or immunoprophylaxis with anti-AT monoclonal antibodies. Staphylococcus aureus causes an array of serious infections resulting in high morbidity and mortality worldwide. This study evaluated naturally occurring serum anti-alpha-toxin (anti-AT) antibody levels in human subjects from various age groups, individuals with S. aureus dialysis and surgical-site infections, and S. aureus-colonized versus noncolonized subjects. Anti-AT immunoglobulin G (IgG) and neutralizing antibody (NAb) levels in infants (aged ≤1 year) were significantly lower than those in other populations. In comparison to adolescent, adult, and elderly populations, young children (aged 2 to 10 years) had equivalent anti-AT IgG levels but significantly lower anti-AT NAb levels. Therefore, the development of anti-AT NAbs appears to occur later than that of AT-specific IgG, suggesting a maturation of the immune response to AT. Anti-AT IgG levels were slightly higher in S. aureus-colonized subjects than in noncolonized subjects. The methicillin susceptibility status of colonizing isolates had no effect on anti-AT antibody levels in S. aureus-colonized subjects. The highest anti-AT IgG and NAb levels were observed in dialysis patients with acute S. aureus infection. Anti-AT IgG and NAb levels were well correlated in subjects aged >10 years, regardless of colonization or infection status. These data demonstrate that AT elicits a robust IgG humoral response in infants and young children that becomes stable prior to adolescence, matures into higher levels of NAbs in healthy adolescents, and becomes elevated during S. aureus infection. These findings may assist in identifying subjects and patient populations that could benefit from vaccination or immunoprophylaxis with anti-AT monoclonal antibodies.Staphylococcus aureus causes an array of serious infections resulting in high morbidity and mortality worldwide. This study evaluated naturally occurring serum anti-alpha-toxin (anti-AT) antibody levels in human subjects from various age groups, individuals with S. aureus dialysis and surgical-site infections, and S. aureus-colonized versus noncolonized subjects. Anti-AT immunoglobulin G (IgG) and neutralizing antibody (NAb) levels in infants (aged ≤1 year) were significantly lower than those in other populations. In comparison to adolescent, adult, and elderly populations, young children (aged 2 to 10 years) had equivalent anti-AT IgG levels but significantly lower anti-AT NAb levels. Therefore, the development of anti-AT NAbs appears to occur later than that of AT-specific IgG, suggesting a maturation of the immune response to AT. Anti-AT IgG levels were slightly higher in S. aureus-colonized subjects than in noncolonized subjects. The methicillin susceptibility status of colonizing isolates had no effect on anti-AT antibody levels in S. aureus-colonized subjects. The highest anti-AT IgG and NAb levels were observed in dialysis patients with acute S. aureus infection. Anti-AT IgG and NAb levels were well correlated in subjects aged >10 years, regardless of colonization or infection status. These data demonstrate that AT elicits a robust IgG humoral response in infants and young children that becomes stable prior to adolescence, matures into higher levels of NAbs in healthy adolescents, and becomes elevated during S. aureus infection. These findings may assist in identifying subjects and patient populations that could benefit from vaccination or immunoprophylaxis with anti-AT monoclonal antibodies. causes an array of serious infections resulting in high morbidity and mortality worldwide. This study evaluated naturally occurring serum anti-alpha-toxin (anti-AT) antibody levels in human subjects from various age groups, individuals with dialysis and surgical-site infections, and -colonized versus noncolonized subjects. Anti-AT immunoglobulin G (IgG) and neutralizing antibody (NAb) levels in infants (aged ≤1 year) were significantly lower than those in other populations. In comparison to adolescent, adult, and elderly populations, young children (aged 2 to 10 years) had equivalent anti-AT IgG levels but significantly lower anti-AT NAb levels. Therefore, the development of anti-AT NAbs appears to occur later than that of AT-specific IgG, suggesting a maturation of the immune response to AT. Anti-AT IgG levels were slightly higher in -colonized subjects than in noncolonized subjects. The methicillin susceptibility status of colonizing isolates had no effect on anti-AT antibody levels in -colonized subjects. The highest anti-AT IgG and NAb levels were observed in dialysis patients with acute infection. Anti-AT IgG and NAb levels were well correlated in subjects aged >10 years, regardless of colonization or infection status. These data demonstrate that AT elicits a robust IgG humoral response in infants and young children that becomes stable prior to adolescence, matures into higher levels of NAbs in healthy adolescents, and becomes elevated during infection. These findings may assist in identifying subjects and patient populations that could benefit from vaccination or immunoprophylaxis with anti-AT monoclonal antibodies. |
Author | Liu, Xu Esser, Mark T. Mok, Hoyin Li, Jia J. Ruzin, Alexey Yu, Li Akhgar, Ahmad Roskos, Lorin K. Wu, Yuling Sellman, Bret R. |
Author_xml | – sequence: 1 givenname: Yuling surname: Wu fullname: Wu, Yuling organization: Clinical Pharmacology and Drug Metabolism/Pharmacokinetics, MedImmune, Gaithersburg, Maryland, USA – sequence: 2 givenname: Xu surname: Liu fullname: Liu, Xu organization: Clinical Pharmacology and Drug Metabolism/Pharmacokinetics, MedImmune, Gaithersburg, Maryland, USA – sequence: 3 givenname: Ahmad surname: Akhgar fullname: Akhgar, Ahmad organization: Clinical Pharmacology and Drug Metabolism/Pharmacokinetics, MedImmune, Gaithersburg, Maryland, USA – sequence: 4 givenname: Jia J. surname: Li fullname: Li, Jia J. organization: Clinical Pharmacology and Drug Metabolism/Pharmacokinetics, MedImmune, Gaithersburg, Maryland, USA – sequence: 5 givenname: Hoyin surname: Mok fullname: Mok, Hoyin organization: Clinical Pharmacology and Drug Metabolism/Pharmacokinetics, MedImmune, Mountain View, California, USA – sequence: 6 givenname: Bret R. surname: Sellman fullname: Sellman, Bret R. organization: Infectious Disease Research, MedImmune, Gaithersburg, Maryland, USA – sequence: 7 givenname: Li surname: Yu fullname: Yu, Li organization: Statistical Sciences, MedImmune, Gaithersburg, Maryland, USA – sequence: 8 givenname: Lorin K. surname: Roskos fullname: Roskos, Lorin K. organization: Clinical Pharmacology and Drug Metabolism/Pharmacokinetics, MedImmune, Gaithersburg, Maryland, USA – sequence: 9 givenname: Mark T. surname: Esser fullname: Esser, Mark T. organization: Infectious Disease/Vaccines Translational Medicine, MedImmune, Gaithersburg, Maryland, USA – sequence: 10 givenname: Alexey surname: Ruzin fullname: Ruzin, Alexey organization: Infectious Disease/Vaccines Translational Medicine, MedImmune, Gaithersburg, Maryland, USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29263109$$D View this record in MEDLINE/PubMed |
BookMark | eNptkUtvEzEUhS1URNPAjjXykgVT7HnZ3iBFBZpIFURqWVsez3XiyrGHsSci_Rf9x5i0RYCQLF0_vnuO7XOGTnzwgNBrSs4pLfn71WJ1TkjLaEHZMzSjRPCiacryBM0IoaIQTctO0VmMt3lZ1zV_gU5LUbZVJmfofj3CXjnwGnAweLW5xMr3-AtMaVTO3lm_wQufbBd6CxGrjbI-Jnyd1LA9uKCD1lPenkbIZeGGrSpuwg_rcR5LUC5tD3g57ZTH11N3CzrFo_5Hu4cxAl6rZMEnvA7D5PI8-PgSPTfKRXj1WOfo2-dPNxfL4urr5epicVXoitapAKJ0wwlnCjTnfWuYEIpXLQcqCBBjeE0qwUzfC2hLTjk3nTGiIz3tCAFdzdGHB91h6nbQ63yN_GI5jHanxoMMysq_T7zdyk3Yy4aXRGTxOXr7KDCG7xPEJHc2anBOeQhTlFQwUQvGyiajb_70-m3ylEMGygdAjyHGEYzUNh3_I1tbJymRv8KWOWx5DFtSlpve_dP0pPtf_CfB6q5Z |
CitedBy_id | crossref_primary_10_1007_s11914_019_00548_4 crossref_primary_10_3389_fimmu_2021_624310 crossref_primary_10_3390_toxins12060408 crossref_primary_10_1016_j_xcrm_2023_101360 crossref_primary_10_1084_jem_20240002 crossref_primary_10_1126_science_abm6380 crossref_primary_10_1093_infdis_jiab219 crossref_primary_10_1093_infdis_jiab326 crossref_primary_10_3390_antibiotics13050410 crossref_primary_10_3346_jkms_2023_38_e129 crossref_primary_10_3389_fimmu_2021_633672 crossref_primary_10_3389_fimmu_2020_620339 crossref_primary_10_1128_spectrum_02399_23 crossref_primary_10_3390_microorganisms6010025 crossref_primary_10_1016_j_chembiol_2022_04_003 crossref_primary_10_1038_s41467_024_52714_7 crossref_primary_10_3390_microorganisms8121936 crossref_primary_10_4049_immunohorizons_2000024 crossref_primary_10_1097_QCO_0000000000000539 |
Cites_doi | 10.1016/j.jinf.2008.01.009 10.1093/infdis/jis192 10.1084/jem.20072208 10.1016/j.meegid.2013.03.020 10.1093/infdis/jit840 10.1093/infdis/jir441 10.1074/jbc.M114.601328 10.1093/cid/ciw333 10.1093/cid/cit123 10.1016/j.cmi.2017.02.035 10.1007/s10096-010-0919-x 10.1128/iai.65.11.4652-4660.1997 10.1164/rccm.201406-1012OC 10.1128/CMR.10.3.505 10.1126/scitranslmed.aad9922 10.1128/AAC.00357-16 10.1086/520200 10.1128/AAC.01020-16 10.1086/515644 10.1128/CVI.05589-11 10.1093/infdis/jiw441 10.3201/eid1312.070629 10.1016/j.tips.2015.11.008 10.1038/nm1207-1405 10.1164/ajrccm.165.7.2105078 10.4161/hv.34414 10.1128/iai.61.12.4972-4979.1993 10.1128/IAI.01313-06 10.1086/656043 10.1016/S1473-3099(05)70295-4 10.1093/infdis/jis462 10.1128/JCM.02023-14 10.1128/mr.55.4.733-751.1991 10.1128/mBio.02272-14 10.1128/iai.57.8.2489-2494.1989 10.1371/journal.pone.0010040 10.1093/cid/ciw245 10.1128/CMR.00134-14 10.1073/pnas.1001815107 10.1128/iai.64.5.1839-1841.1996 |
ContentType | Journal Article |
Copyright | Copyright © 2018 American Society for Microbiology. Copyright © 2018 American Society for Microbiology. 2018 American Society for Microbiology |
Copyright_xml | – notice: Copyright © 2018 American Society for Microbiology. – notice: Copyright © 2018 American Society for Microbiology. 2018 American Society for Microbiology |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
DOI | 10.1128/IAI.00671-17 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Biology |
DocumentTitleAlternate | Prevalence of Anti-AT Antibodies in Human Subjects |
EISSN | 1098-5522 |
ExternalDocumentID | PMC5820940 29263109 10_1128_IAI_00671_17 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: ; |
GroupedDBID | --- -DZ -~X .55 .GJ 0R~ 18M 29I 2WC 39C 3O- 4.4 41~ 53G 5GY 5RE 5VS 85S AAGFI AAYXX ABOCM ACGFO ADBBV ADXHL AENEX AGCDD AGVNZ AI. ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW C1A CITATION CS3 D0S DIK DU5 E3Z EBS EJD F5P FRP GX1 H13 HYE HZ~ H~9 IH2 J5H KQ8 L7B MVM NEJ O9- OHT OK1 P2P RHI RNS RPM RSF SJN TR2 TWZ UPT VH1 W2D W8F WH7 WHG WOQ X7M Y6R ZGI ZXP ~KM CGR CUY CVF ECM EIF NPM 7X8 5PM |
ID | FETCH-LOGICAL-c314t-e0ac58087aec88d6f799a8368e190e0ff840397fdd9e628188fbff9b0d1b00ec3 |
ISSN | 0019-9567 1098-5522 |
IngestDate | Thu Aug 21 18:32:26 EDT 2025 Fri Jul 11 08:00:54 EDT 2025 Mon Jul 21 05:48:19 EDT 2025 Thu Apr 24 23:04:32 EDT 2025 Tue Jul 01 02:09:23 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | alpha-toxin human subjects serum antibodies Staphylococcus aureus |
Language | English |
License | Copyright © 2018 American Society for Microbiology. All Rights Reserved. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c314t-e0ac58087aec88d6f799a8368e190e0ff840397fdd9e628188fbff9b0d1b00ec3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Citation Wu Y, Liu X, Akhgar A, Li JJ, Mok H, Sellman BR, Yu L, Roskos LK, Esser MT, Ruzin A. 2018. Prevalence of IgG and neutralizing antibodies against Staphylococcus aureus alpha-toxin in healthy human subjects and diverse patient populations. Infect Immun 86:e00671-17. https://doi.org/10.1128/IAI.00671-17. |
OpenAccessLink | https://iai.asm.org/content/iai/86/3/e00671-17.full.pdf |
PMID | 29263109 |
PQID | 1979497725 |
PQPubID | 23479 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5820940 proquest_miscellaneous_1979497725 pubmed_primary_29263109 crossref_citationtrail_10_1128_IAI_00671_17 crossref_primary_10_1128_IAI_00671_17 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2018-03-01 |
PublicationDateYYYYMMDD | 2018-03-01 |
PublicationDate_xml | – month: 03 year: 2018 text: 2018-03-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: 1752 N St., N.W., Washington, DC |
PublicationTitle | Infection and immunity |
PublicationTitleAlternate | Infect Immun |
PublicationYear | 2018 |
Publisher | American Society for Microbiology |
Publisher_xml | – name: American Society for Microbiology |
References | e_1_3_2_26_2 e_1_3_2_27_2 e_1_3_2_28_2 e_1_3_2_29_2 e_1_3_2_41_2 e_1_3_2_40_2 e_1_3_2_20_2 e_1_3_2_43_2 e_1_3_2_21_2 e_1_3_2_42_2 e_1_3_2_22_2 e_1_3_2_23_2 e_1_3_2_24_2 e_1_3_2_25_2 National Institute for Biological Standards and Controls (e_1_3_2_44_2) 2010 e_1_3_2_9_2 e_1_3_2_15_2 e_1_3_2_38_2 e_1_3_2_8_2 e_1_3_2_16_2 e_1_3_2_37_2 e_1_3_2_7_2 e_1_3_2_17_2 e_1_3_2_6_2 e_1_3_2_18_2 e_1_3_2_39_2 e_1_3_2_19_2 e_1_3_2_30_2 e_1_3_2_32_2 e_1_3_2_10_2 e_1_3_2_31_2 e_1_3_2_5_2 e_1_3_2_11_2 e_1_3_2_34_2 e_1_3_2_4_2 e_1_3_2_12_2 e_1_3_2_33_2 e_1_3_2_3_2 e_1_3_2_13_2 e_1_3_2_36_2 e_1_3_2_2_2 e_1_3_2_14_2 e_1_3_2_35_2 16310147 - Lancet Infect Dis. 2005 Dec;5(12):751-62 9353046 - Infect Immun. 1997 Nov;65(11):4652-60 8613399 - Infect Immun. 1996 May;64(5):1839-41 23446627 - Clin Infect Dis. 2013 Jun;56(11):1554-61 25392350 - J Clin Microbiol. 2015 Jan;53(1):227-36 23619097 - Infect Genet Evol. 2014 Jan;21:531-41 9697723 - J Infect Dis. 1998 Aug;178(2):431-40 27795368 - Antimicrob Agents Chemother. 2016 Dec 27;61(1):null 25303310 - Am J Respir Crit Care Med. 2014 Nov 15;190(10):1139-48 9227864 - Clin Microbiol Rev. 1997 Jul;10(3):505-20 18268041 - J Exp Med. 2008 Feb 18;205(2):287-94 20383551 - Eur J Clin Microbiol Infect Dis. 2010 Jun;29(6):715-25 27651418 - J Infect Dis. 2016 Dec 1;214(11):1638-1646 28274770 - Clin Microbiol Infect. 2017 Apr;23 (4):219-221 22474035 - J Infect Dis. 2012 Aug 1;206(3):352-6 26016486 - Clin Microbiol Rev. 2015 Jul;28(3):603-61 8225571 - Infect Immun. 1993 Dec;61(12):4972-9 25210036 - J Biol Chem. 2014 Oct 24;289(43):29874-80 22807524 - J Infect Dis. 2012 Sep 15;206(6):915-23 27324766 - Antimicrob Agents Chemother. 2016 Aug 22;60(9):5312-21 26719219 - Trends Pharmacol Sci. 2016 Mar;37(3):231-241 24376272 - J Infect Dis. 2014 Jun 1;209(11):1773-80 18064027 - Nat Med. 2007 Dec;13(12):1405-6 21849291 - J Infect Dis. 2011 Sep 15;204(6):937-41 11934711 - Am J Respir Crit Care Med. 2002 Apr 1;165(7):867-903 25691592 - MBio. 2015 Feb 17;6(1):e02272-14 17101657 - Infect Immun. 2007 Feb;75(2):1040-4 26962155 - Sci Transl Med. 2016 Mar 9;8(329):329ra31 18314197 - J Infect. 2008 Apr;56(4):249-56 20386721 - PLoS One. 2010 Apr 06;5(4):e10040 18258033 - Emerg Infect Dis. 2007 Dec;13(12):1840-6 22237895 - Clin Vaccine Immunol. 2012 Mar;19(3):377-85 27208045 - Clin Infect Dis. 2016 Sep 1;63(5):657-62 10476727 - Clin Infect Dis. 1999 Aug;29(2):281-8 20624979 - Proc Natl Acad Sci U S A. 2010 Jul 27;107(30):13473-8 2744856 - Infect Immun. 1989 Aug;57(8):2489-94 20726702 - J Infect Dis. 2010 Oct 1;202(7):1050-8 27481953 - Clin Infect Dis. 2016 Aug 15;63 Suppl 2:S46-51 25483694 - Hum Vaccin Immunother. 2015;11(3):632-41 1779933 - Microbiol Rev. 1991 Dec;55(4):733-51 |
References_xml | – ident: e_1_3_2_28_2 doi: 10.1016/j.jinf.2008.01.009 – ident: e_1_3_2_19_2 doi: 10.1093/infdis/jis192 – ident: e_1_3_2_23_2 doi: 10.1084/jem.20072208 – ident: e_1_3_2_2_2 doi: 10.1016/j.meegid.2013.03.020 – ident: e_1_3_2_43_2 – volume-title: NIBSC code: STA, vol 5.0, p 1–4 year: 2010 ident: e_1_3_2_44_2 – ident: e_1_3_2_20_2 doi: 10.1093/infdis/jit840 – ident: e_1_3_2_18_2 doi: 10.1093/infdis/jir441 – ident: e_1_3_2_30_2 doi: 10.1074/jbc.M114.601328 – ident: e_1_3_2_9_2 doi: 10.1093/cid/ciw333 – ident: e_1_3_2_29_2 doi: 10.1093/cid/cit123 – ident: e_1_3_2_33_2 doi: 10.1016/j.cmi.2017.02.035 – ident: e_1_3_2_42_2 – ident: e_1_3_2_27_2 doi: 10.1007/s10096-010-0919-x – ident: e_1_3_2_15_2 doi: 10.1128/iai.65.11.4652-4660.1997 – ident: e_1_3_2_41_2 doi: 10.1164/rccm.201406-1012OC – ident: e_1_3_2_4_2 doi: 10.1128/CMR.10.3.505 – ident: e_1_3_2_13_2 doi: 10.1126/scitranslmed.aad9922 – ident: e_1_3_2_21_2 doi: 10.1128/AAC.00357-16 – ident: e_1_3_2_35_2 doi: 10.1086/520200 – ident: e_1_3_2_31_2 doi: 10.1128/AAC.01020-16 – ident: e_1_3_2_34_2 doi: 10.1086/515644 – ident: e_1_3_2_25_2 doi: 10.1128/CVI.05589-11 – ident: e_1_3_2_38_2 doi: 10.1093/infdis/jiw441 – ident: e_1_3_2_7_2 doi: 10.3201/eid1312.070629 – ident: e_1_3_2_8_2 doi: 10.1016/j.tips.2015.11.008 – ident: e_1_3_2_17_2 doi: 10.1038/nm1207-1405 – ident: e_1_3_2_5_2 doi: 10.1164/ajrccm.165.7.2105078 – ident: e_1_3_2_36_2 doi: 10.4161/hv.34414 – ident: e_1_3_2_11_2 doi: 10.1128/iai.61.12.4972-4979.1993 – ident: e_1_3_2_16_2 doi: 10.1128/IAI.01313-06 – ident: e_1_3_2_24_2 doi: 10.1086/656043 – ident: e_1_3_2_3_2 doi: 10.1016/S1473-3099(05)70295-4 – ident: e_1_3_2_26_2 doi: 10.1093/infdis/jis462 – ident: e_1_3_2_37_2 doi: 10.1128/JCM.02023-14 – ident: e_1_3_2_10_2 doi: 10.1128/mr.55.4.733-751.1991 – ident: e_1_3_2_40_2 doi: 10.1128/mBio.02272-14 – ident: e_1_3_2_14_2 doi: 10.1128/iai.57.8.2489-2494.1989 – ident: e_1_3_2_39_2 doi: 10.1371/journal.pone.0010040 – ident: e_1_3_2_32_2 doi: 10.1093/cid/ciw245 – ident: e_1_3_2_6_2 doi: 10.1128/CMR.00134-14 – ident: e_1_3_2_12_2 doi: 10.1073/pnas.1001815107 – ident: e_1_3_2_22_2 doi: 10.1128/iai.64.5.1839-1841.1996 – reference: 2744856 - Infect Immun. 1989 Aug;57(8):2489-94 – reference: 18258033 - Emerg Infect Dis. 2007 Dec;13(12):1840-6 – reference: 25210036 - J Biol Chem. 2014 Oct 24;289(43):29874-80 – reference: 17101657 - Infect Immun. 2007 Feb;75(2):1040-4 – reference: 18064027 - Nat Med. 2007 Dec;13(12):1405-6 – reference: 20726702 - J Infect Dis. 2010 Oct 1;202(7):1050-8 – reference: 25483694 - Hum Vaccin Immunother. 2015;11(3):632-41 – reference: 10476727 - Clin Infect Dis. 1999 Aug;29(2):281-8 – reference: 22474035 - J Infect Dis. 2012 Aug 1;206(3):352-6 – reference: 27481953 - Clin Infect Dis. 2016 Aug 15;63 Suppl 2:S46-51 – reference: 20386721 - PLoS One. 2010 Apr 06;5(4):e10040 – reference: 26016486 - Clin Microbiol Rev. 2015 Jul;28(3):603-61 – reference: 27208045 - Clin Infect Dis. 2016 Sep 1;63(5):657-62 – reference: 24376272 - J Infect Dis. 2014 Jun 1;209(11):1773-80 – reference: 9697723 - J Infect Dis. 1998 Aug;178(2):431-40 – reference: 1779933 - Microbiol Rev. 1991 Dec;55(4):733-51 – reference: 25392350 - J Clin Microbiol. 2015 Jan;53(1):227-36 – reference: 18314197 - J Infect. 2008 Apr;56(4):249-56 – reference: 9353046 - Infect Immun. 1997 Nov;65(11):4652-60 – reference: 9227864 - Clin Microbiol Rev. 1997 Jul;10(3):505-20 – reference: 22237895 - Clin Vaccine Immunol. 2012 Mar;19(3):377-85 – reference: 18268041 - J Exp Med. 2008 Feb 18;205(2):287-94 – reference: 26719219 - Trends Pharmacol Sci. 2016 Mar;37(3):231-241 – reference: 20383551 - Eur J Clin Microbiol Infect Dis. 2010 Jun;29(6):715-25 – reference: 21849291 - J Infect Dis. 2011 Sep 15;204(6):937-41 – reference: 11934711 - Am J Respir Crit Care Med. 2002 Apr 1;165(7):867-903 – reference: 23619097 - Infect Genet Evol. 2014 Jan;21:531-41 – reference: 8613399 - Infect Immun. 1996 May;64(5):1839-41 – reference: 20624979 - Proc Natl Acad Sci U S A. 2010 Jul 27;107(30):13473-8 – reference: 26962155 - Sci Transl Med. 2016 Mar 9;8(329):329ra31 – reference: 23446627 - Clin Infect Dis. 2013 Jun;56(11):1554-61 – reference: 28274770 - Clin Microbiol Infect. 2017 Apr;23 (4):219-221 – reference: 16310147 - Lancet Infect Dis. 2005 Dec;5(12):751-62 – reference: 22807524 - J Infect Dis. 2012 Sep 15;206(6):915-23 – reference: 27795368 - Antimicrob Agents Chemother. 2016 Dec 27;61(1):null – reference: 27324766 - Antimicrob Agents Chemother. 2016 Aug 22;60(9):5312-21 – reference: 27651418 - J Infect Dis. 2016 Dec 1;214(11):1638-1646 – reference: 8225571 - Infect Immun. 1993 Dec;61(12):4972-9 – reference: 25691592 - MBio. 2015 Feb 17;6(1):e02272-14 – reference: 25303310 - Am J Respir Crit Care Med. 2014 Nov 15;190(10):1139-48 |
SSID | ssj0014448 |
Score | 2.3530016 |
Snippet | Staphylococcus aureus
causes an array of serious infections resulting in high morbidity and mortality worldwide. This study evaluated naturally occurring serum... causes an array of serious infections resulting in high morbidity and mortality worldwide. This study evaluated naturally occurring serum anti-alpha-toxin... Staphylococcus aureus causes an array of serious infections resulting in high morbidity and mortality worldwide. This study evaluated naturally occurring serum... |
SourceID | pubmedcentral proquest pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
SubjectTerms | Adolescent Adult Aged Antibodies, Bacterial - blood Antibodies, Neutralizing - blood Bacterial Toxins - immunology Child Child, Preschool Enzyme-Linked Immunosorbent Assay Female Healthy Volunteers Hemolysin Proteins - immunology Humans Immunoglobulin G - blood Infant Male Microbial Immunity and Vaccines Middle Aged Prospective Studies Staphylococcal Infections - blood Staphylococcal Infections - immunology Staphylococcal Infections - microbiology Staphylococcus aureus - genetics Staphylococcus aureus - immunology Staphylococcus aureus - physiology Young Adult |
Title | Prevalence of IgG and Neutralizing Antibodies against Staphylococcus aureus Alpha-Toxin in Healthy Human Subjects and Diverse Patient Populations |
URI | https://www.ncbi.nlm.nih.gov/pubmed/29263109 https://www.proquest.com/docview/1979497725 https://pubmed.ncbi.nlm.nih.gov/PMC5820940 |
Volume | 86 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKEIgXBANGuclI8FRlxGku9mPFbR3axEMn9S1yHLsNl2TaEmnbb-CFf8zxJZduQxpIVVq5ThrlfD03f-cYoTcqgegm84UXKBl4YZRxj6oo9rhu3h4psOpSpwYODuO9o3B_GS1Ho18D1lJTZ7vi4tq6kv-RKoyBXHWV7D9ItrsoDMBnkC8cQcJwvJGMdf8lbqqGTEXI6rNZCjiUjUlfXJiMR1kXWaWpghO-4gU4g9q_hGcLRqwSooHh5kTC20wX3XqL6qww3EdbnnTukvygXr4Z2ochLhsqh9Td_XUx5eRrtwfY6dDVnTual2U7F6YOpe4T-I1R_poHv-pIQYUZXDYdCr-vV5YAPlv_5Hk_z2Cv4JP93WHWgtCettVqYsI8iM2ssZVW-ereplEUbGhn1yi76IP3q0o_0IUM89lck_QS4pGkN27tgv4lm9cxEU0MFNAUzk7N2SlJbqHbAQQdej-MD_Mv3ZpUGIbOrts7b8soAvpu-NubDs6VqOUy-XbgzSweoPsuDMEzi6mHaCTLbXTHbkx6vo3uHjjKxSP0uwcZrhQGkGGQJx6CDPcgww5keBNk2IIMD0CG4eVAhg3IcAsyc30HMuxAhgcge4yOPn1cvN_z3D4enpiSsPakz0VEfZpwKSjNY5Uwxuk0phK8UekrRUMf3GKV50zGujsZVZlSLPNzAkZBiukTtFVWpXyKMI9zyVgo8pjJUAqesWnsEwExfS5jxskYTdqHnwrX5F7vtfIjvU7QY_S2m31sm7v8Zd7rVo4paF-9pMZLWTWnKWFgzyCECqIx2rFy7a4UsCDWfXfHKNmQeDdBd3bf_KYs1qbDewR-OQv9Zze8v-foXv8fe4G26pNGvgRfuc5eGQj_AUVzw4I |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prevalence+of+IgG+and+Neutralizing+Antibodies+against+Staphylococcus+aureus+Alpha-Toxin+in+Healthy+Human+Subjects+and+Diverse+Patient+Populations&rft.jtitle=Infection+and+immunity&rft.au=Wu%2C+Yuling&rft.au=Liu%2C+Xu&rft.au=Akhgar%2C+Ahmad&rft.au=Li%2C+Jia+J.&rft.date=2018-03-01&rft.issn=0019-9567&rft.eissn=1098-5522&rft.volume=86&rft.issue=3&rft_id=info:doi/10.1128%2FIAI.00671-17&rft.externalDBID=n%2Fa&rft.externalDocID=10_1128_IAI_00671_17 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0019-9567&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0019-9567&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0019-9567&client=summon |